skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Structural Basis for Resistance to Diverse Classes of NAMPT Inhibitors

Journal Article · · PLoS ONE
 [1];  [1];  [1];  [2];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [1];  [2];  [2];  [1];  [1];  [3]
  1. Genentech, Inc., South San Francisco, CA (United States)
  2. Forma Therapeutics, Inc., Watertown, MA (United States)
  3. Univ. of Washington, Seattle, WA (United States)
+ Show Author Affiliations

Inhibiting NAD biosynthesis by blocking the function of nicotinamide phosphoribosyl transferase (NAMPT) is an attractive therapeutic strategy for targeting tumor metabolism. However, the development of drug resistance commonly limits the efficacy of cancer therapeutics. This study identifies mutations in NAMPT that confer resistance to a novel NAMPT inhibitor, GNE-618, in cell culture and in vivo, thus demonstrating that the cytotoxicity of GNE-618 is on target. We determine the crystal structures of six NAMPT mutants in the apo form and in complex with various inhibitors and use cellular, biochemical and structural data to elucidate two resistance mechanisms. One is the surprising finding of allosteric modulation by mutation of residue Ser165, resulting in unwinding of an α-helix that binds the NAMPT substrate 5-phosphoribosyl-1-pyrophosphate (PRPP). The other mechanism is orthosteric blocking of inhibitor binding by mutations of Gly217. Furthermore, by evaluating a panel of diverse small molecule inhibitors, we unravel inhibitor structure activity relationships on the mutant enzymes. These results provide valuable insights into the design of next generation NAMPT inhibitors that offer improved therapeutic potential by evading certain mechanisms of resistance.

Research Organization:
Argonne National Laboratory (ANL), Argonne, IL (United States)
Sponsoring Organization:
USDOE Office of Science (SC), Biological and Environmental Research (BER); National Institutes of Health (NIH)
OSTI ID:
1255305
Journal Information:
PLoS ONE, Vol. 9, Issue 10; ISSN 1932-6203
Publisher:
Public Library of ScienceCopyright Statement
Country of Publication:
United States
Language:
ENGLISH
Citation Metrics:
Cited by: 23 works
Citation information provided by
Web of Science

References (34)

Structure-Based Identification of Ureas as Novel Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors journal June 2013
Pharmacological Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD + Biosynthesis, in Human Cancer Cells : METABOLIC BASIS AND POTENTIAL CLINICAL IMPLICATIONS journal December 2012
Refinement of Macromolecular Structures by the Maximum-Likelihood Method journal May 1997
PHENIX: a comprehensive Python-based system for macromolecular structure solution. text January 2010
Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme journal June 2006
Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3weeks in solid tumours: An ECSG/EORTC study journal March 2005
A phosphoenzyme mimic, overlapping catalytic sites and reaction coordinate motion for human NAMPT journal August 2009
Coot model-building tools for molecular graphics journal November 2004
Supplementation of Nicotinic Acid with NAMPT Inhibitors Results in Loss of In Vivo Efficacy in NAPRT1-Deficient Tumor Models journal December 2013
The Small Molecule GMX1778 Is a Potent Inhibitor of NAD+ Biosynthesis: Strategy for Enhanced Therapy in Nicotinic Acid Phosphoribosyltransferase 1-Deficient Tumors journal August 2009
Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase journal December 2010
The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor journal October 2007
Structure and reaction mechanism of human nicotinamide phosphoribosyltransferase journal October 2009
Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT) journal October 2013
The Secret Life of NAD + : An Old Metabolite Controlling New Metabolic Signaling Pathways journal April 2010
Dependence of Tumor Cell Lines and Patient-Derived Tumors on the NAD Salvage Pathway Renders Them Sensitive to NAMPT Inhibition with GNE-618 journal October 2013
A Preclinical Study on the Rescue of Normal Tissue by Nicotinic Acid in High-Dose Treatment with APO866, a Specific Nicotinamide Phosphoribosyltransferase Inhibitor journal June 2010
Nampt/PBEF/visfatin and cancer journal July 2010
Structural and Biochemical Analyses of the Catalysis and Potency Impact of Inhibitor Phosphoribosylation by Human Nicotinamide Phosphoribosyltransferase journal May 2014
NAMPT in Regulated NAD Biosynthesis and its Pivotal Role in Human Metabolism journal May 2011
Visfatin/NAMPT: A Multifaceted Molecule with Diverse Roles in Physiology and Pathophysiology journal August 2012
Fragment-Based Identification of Amides Derived from trans -2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT) journal January 2014
Nampt: linking NAD biology, metabolism and cancer journal April 2009
Elevation of Cellular NAD Levels by Nicotinic Acid and Involvement of Nicotinic Acid Phosphoribosyltransferase in Human Cells journal June 2007
Anticancer agent CHS-828 inhibits cellular synthesis of NAD journal March 2008
Safety and efficacy of NAD depleting cancer drugs: results of a phase I clinical trial of CHS 828 and overview of published data journal September 2009
XDS journal January 2010
Structure-Based Discovery of Novel Amide-Containing Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors journal July 2013
PHENIX: a comprehensive Python-based system for macromolecular structure solution journal January 2010
Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties journal June 2013
Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents journal June 2006
Enzymatic Synthesis of Nicotinamide Mononucleotide journal April 1957
Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors journal October 2013
[20] Processing of X-ray diffraction data collected in oscillation mode book January 1997

Cited By (6)

Identification of a novel NAMPT inhibitor by CRISPR/Cas9 chemogenomic profiling in mammalian cells text January 2017
Cancer cell metabolic plasticity allows resistance to NAMPT inhibition but invariably induces dependence on LDHA journal March 2018
Extracellular nicotinamide phosphoribosyltransferase, a new cancer metabokine journal June 2016
Cross resistance to diverse anticancer nicotinamide phosphoribosyltransferase inhibitors induced by FK866 treatment journal March 2018
Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities journal June 2016
New strategies to maximize therapeutic opportunities for NAMPT inhibitors in oncology journal June 2015

Similar Records

Discovery and Characterization of Novel Nonsubstrate and Substrate NAMPT Inhibitors
Journal Article · Wed May 03 00:00:00 EDT 2017 · Molecular Cancer Therapeutics · OSTI ID:1255305
+30 more
A Phosphoenzyme Mimic, Overlapping Catalytic Sites and Reaction Coordinate Motion for Human NAMPT
Journal Article · Thu Jan 01 00:00:00 EST 2009 · Proceedings of the National Academy of Sciences of the United States of America · OSTI ID:1255305
+1 more
Comprehensive X-Ray Structural Studies of the Quinolinate Phosphoribosyl Transferase (BNA6) From Saccharomyces Cerevisiae
Journal Article · Thu May 14 00:00:00 EDT 2009 · Biochem.47:4039,2008 · OSTI ID:1255305

Related Subjects

59 BASIC BIOLOGICAL SCIENCES
Crystal structure
Enzyme structure
Enzyme inhibitors
Imidazole
Enzymes
Protein structure
Mutation detection
Nicotine